These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16615905)

  • 21. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
    Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
    J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
    Carter PH; Tebben AJ
    Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functionally selective synthetic mimic of the HIV-1 co-receptor CXCR4.
    Möbius K; Dürr R; Haussner C; Dietrich U; Eichler J
    Chemistry; 2012 Jul; 18(27):8292-5. PubMed ID: 22692798
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.
    Imai M; Baranyi L; Okada N; Okada H
    Biochem Biophys Res Commun; 2007 Feb; 353(4):851-6. PubMed ID: 17210123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking.
    Pérez-Nueno VI; Ritchie DW; Rabal O; Pascual R; Borrell JI; Teixidó J
    J Chem Inf Model; 2008 Mar; 48(3):509-33. PubMed ID: 18298095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
    Thoma G; Streiff MB; Kovarik J; Glickman F; Wagner T; Beerli C; Zerwes HG
    J Med Chem; 2008 Dec; 51(24):7915-20. PubMed ID: 19053768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics.
    Suresh P; Wanchu A
    J Postgrad Med; 2006; 52(3):210-7. PubMed ID: 16855325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV coreceptor phenotyping in the clinical setting.
    Low AJ; Swenson LC; Harrigan PR
    AIDS Rev; 2008; 10(3):143-51. PubMed ID: 18820716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCR4, inhibitors and mechanisms of action.
    Liang X
    Chem Biol Drug Des; 2008 Aug; 72(2):97-110. PubMed ID: 18624812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin.
    Springael JY; de Poorter C; Deupi X; Van Durme J; Pardo L; Parmentier M
    Cell Signal; 2007 Jul; 19(7):1446-56. PubMed ID: 17320349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.
    Binninger-Schinzel D; Müller D; Wolf T; Krause B; Meye B; Winskowsky G; Raupp S; Norley S; Brodt R; Werner A
    J Med Virol; 2008 Feb; 80(2):192-200. PubMed ID: 18098144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introducing the issue on "differential use of CCR5 versus CXCR4 by HIV-1. Pathogenic, translational and clinical open questions".
    Poli G; Buonaguro L
    J Transl Med; 2011 Jan; 9 Suppl 1(Suppl 1):I1. PubMed ID: 21284898
    [No Abstract]   [Full Text] [Related]  

  • 34. Engineering and screening the N-terminus of chemokines for drug discovery.
    Chevigné A; Fievez V; Schmit JC; Deroo S
    Biochem Pharmacol; 2011 Nov; 82(10):1438-56. PubMed ID: 21824467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [HIV and chemokine receptors. New explanations of the biology and virulence of the virus].
    Fenyö EM; Samuelsson A
    Lakartidningen; 1997 Mar; 94(10):824-8. PubMed ID: 9102508
    [No Abstract]   [Full Text] [Related]  

  • 36. [Three dimensional structure of CXC chemokines and its implication for the receptor recognition].
    Haruyama H; Hanzawa H
    Tanpakushitsu Kakusan Koso; 1997 May; 42(7 Suppl):982-8. PubMed ID: 9170911
    [No Abstract]   [Full Text] [Related]  

  • 37. Classification of protein folds.
    Russell RB
    Methods Mol Biol; 2000; 143():305-24. PubMed ID: 11084911
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemokine structure and receptor interactions.
    Handel TM; Lau EK
    Ernst Schering Res Found Workshop; 2004; (45):101-24. PubMed ID: 14699797
    [No Abstract]   [Full Text] [Related]  

  • 39. Semi-synthesis of chemokines.
    Beck-Sickinger AG; Panitz N
    Curr Opin Chem Biol; 2014 Oct; 22():100-7. PubMed ID: 25299571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural biology. Viral chemokine mimicry.
    Standfuss J
    Science; 2015 Mar; 347(6226):1071-2. PubMed ID: 25745149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.